Boehringer Ingelheim Licenses BaroFold's PreEMT High-Pressure Protein-Refolding Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Boehringer Ingelheim Licenses BaroFold's PreEMT High-Pressure Protein-Refolding Technology


Pharmaceutical Technology Europe

Boehringer Ingelheim has entered into a non-exclusive technology and commercial license option agreement with BaroFold. Under the terms of the agreement, Boehringer Ingelheim will license BaroFold's pressure-enabled manufacturing technology (PreEMT). A laboratory-scale reactor of the PreEMT high-pressure protein-refolding technology will be installed at Boehringer Ingelheim's microbial facility in Vienna, Austria. The technology will be used for the development of biopharmaceutical production processes.

PreEMT uses high pressure to disaggregate and control the refolding of recombinant proteins to their native structures at yields and efficiencies that cannot be achieved with existing technologies. PreEMT can substantially reduce the cost of manufacturing because of its increased yield and throughput at high protein concentrations. The technology is readily scalable and has been used for the cGMP production of clinical materials for Phase I to Phase III trials.

Georg Klima, executive director of Process Science Austria at Boehringer Ingelheim, said in a press statement, "This collaboration builds upon the exciting work we have completed with BaroFold over the last 18 months and enhances our strategy to integrate the most innovative technologies for biologic manufacturing. We will be able to leverage BaroFold's high pressure refold technology on a variety of proteins under development at our facility in Vienna."

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here